Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 14

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 14
---
 markets that develop would be affected by many factors independent of and in addition to the foregoing, including the time remaining to the maturity of the Notes, the outstanding amount of the Notes and the level, direction and volatility of market interest rates generally.

<div align='center'>S-9</div>

### USE OF PROCEEDS
TUSFI expects to receive a total of approximately $2,375.4 million in net proceeds from this offering, after deducting underwriting discounts and estimated offering expenses payable by TUSFI. TUSFI intends to remit the net proceeds from the offering of the Notes via intercompany loans and intercompany dividends to TPC. TPC intends to use such proceeds primarily to pay down its short-term borrowings such as certain of its outstanding commercial paper and the $500.0 million short-term loan originally incurred to pre-pay its then outstanding long-term borrowings in the fiscal year ended March 31, 2025.

As of March 31, 2025, TPC’s short-term drawings outstanding under its short-term commercial paper facility totaled approximately ¥270.0 billion, and were subject to a weighted average interest rate of approximately 0.57%. TPC intends to reduce such drawings using the net proceeds both from the offering of the Notes and from the offering of an aggregate principal amount of ¥184.0 billion Japanese yen-denominated senior notes issued on June 12, 2025. The $500.0 million short-term loan is currently being rolled over on a monthly basis and is subject to a floating interest rate (one-month SOFR plus a fixed spread). TPC will use any remaining proceeds for paying down other indebtedness and general corporate purposes.

<div align='center'>S-10</div>

### CAPITALIZATION AND INDEBTEDNESS
The following table sets forth Takeda’s consolidated capitalization and indebtedness as of March 31, 2025 presented in accordance with IFRS, on an actual basis and on an as adjusted basis to give effect to the offering and sale of the Notes, but not the use of proceeds therefrom. You should read this table in conjunction with the consolidated financial statements and related notes incorporated by reference in this prospectus supplement.

|                                              |     | As of March 31, 2025 |         |     |               |         |       |
|:---------------------------------------------|:----|:---------------------|--------:|:----|:--------------|--------:|------:|
|                                              |     | Actual               |